SCHEMBL4816736

SCHEMBL4816736

CCOc1ccc2c(N)cccc2n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.46
ADORA1 P30542 3/20 0.43
HTR3A P46098 1/20 0.43
NCF1 P14598 10/20 0.43
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
KDM4E B2RXH2 1/20 0.42
LMNA P02545 1/20 0.42
GLA P06280 1/20 0.42
POLB P06746 1/20 0.42
GAA P10253 1/20 0.42
HPGD P15428 1/20 0.42
PTBP1 P26599 1/20 0.42
KMT2A Q03164 1/20 0.42
RCE1 Q9Y256 1/20 0.42
CYBB P04839 4/20 0.42
NOX5 Q96PH1 1/20 0.42
MAPK1 P28482 1/20 0.42
ADORA2A P29274 2/20 0.41
TLR8 Q9NR97 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL827147 0.81 ADORA1 (0.44) ADORA1NCF1RAB9AKDM4ELMNA
SCHEMBL31179390 0.81 HTR3A (0.46) ALDH1A1HTR3ANCF1NPC1RAB9A
SCHEMBL3532637 0.81 HTR3A (0.46) ALDH1A1HTR3ANCF1NPC1RAB9A
SCHEMBL10645201 0.80 NCF1 (0.54) ALDH1A1HTR3ANCF1NPC1RAB9A
SCHEMBL31492115 0.80 NCF1 (0.54) ALDH1A1HTR3ANCF1NPC1RAB9A
SCHEMBL2525163 0.75 MAPK8 (0.56) ALDH1A1ADORA1NPC1RAB9AMAPK1
SCHEMBL4824153 0.74 ALDH1A1 (0.60) ALDH1A1NPC1RAB9ALMNAPOLB
SCHEMBL5200482 0.74 TSPO (0.49) ALDH1A1NPC1RAB9AKDM4ELMNA
SCHEMBL4820896 0.74 HTR3A (0.46) ALDH1A1HTR3ANCF1NPC1RAB9A
Hydrogen Peroxide SCHEMBL28177611 0.74 MAPT (0.53) ALDH1A1ADORA1NPC1RAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1659144-B Quinoline and isoquinoline derivatives, process for their preparation and their use as inflammation inhibitors SCHERING AG 2010-09-08 CN disclosed
US-7329753-B2 Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors SCHERING AG (DE) 2008-02-12 US disclosed
EP-1492771-B1 QUINOLINE AND ISOQUINOLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS ANTI-INFLAMMATORY AGENTS SCHERING AG (DE) 2007-02-28 EP disclosed
US-20060229333-A1 Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2006-10-12 US disclosed
US-7109212-B2 Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors SCHERING AG (DE) 2006-09-19 US disclosed
CN-1659144-A Quinoline and isoquinoline derivatives, process for their preparation and their use as inflammation inhibitors SCHERING AG (DE) 2005-08-24 CN disclosed
US-20050165050-A1 Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2005-07-28 US disclosed
US-6897224-B2 Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors SCHERING AG (DE) 2005-05-24 US disclosed
EP-1492771-A1 QUINOLINE AND ISOQUINOLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS ANTI-INFLAMMATORY AGENTS SCHERING AKTIENGESELLSCHAFT (DE) 2005-01-05 EP disclosed
US-20040116694-A1 Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors SCHERING AG (DE) 2004-06-17 US disclosed
WO-2003082827-A1 QUINOLINE AND ISOQUINOLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS ANTI-INFLAMMATORY AGENTS SCHERING AKTIENGESELLSCHAFT (DE) 2003-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060229333-A1 Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors NFKBIA, IL1B, IRF3 ALDH1A1 1538/4885ADORA1 2967/4885HTR3A 2704/4885
US-20050165050-A1 Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors NFKBIA, IL1B, IRF3 ALDH1A1 1538/4885ADORA1 2967/4885HTR3A 2704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.